


PHARMACEUTICAL 2022



INTEGRATED BIOPHARMA INC Rank 12 of 475







RealRate

PHARMACEUTICAL 2022



INTEGRATED BIOPHARMA INC Rank 12 of 475

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 1,326% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 1,134% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 541% points above the market average of -276%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 17,998 |
| Cost of Goods Sold | 54,079 |
| Intangible Assets | 0 |
| Liabilities, Current | 9,236 |
| Liabilities, Non-Current | 1,870 |
| Other Assets | 5,700 |
| Other Compr. Net Income | 0 |
| Other Expenses | -766 |
| Other Liabilities | 0 |
| Other Net Income | 1,463 |
| Property and Equipment | 1,742 |
| Research and Development | 0 |
| Revenues | 63,559 |
| Selling, General and Administrative Expense | 3,696 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 25,440 |
| Liabilities | 11,106 |
| Expenses | 57,009 |
| Stockholders Equity | 14,334 |
| Net Income | 8,013 |
| Comprehensive Net Income | 8,013 |
| Economic Capital Ratio | 264% |

